The XENERA™ 1 Study Tests Xentuzumab in Combination With Everolimus and Exemestane in Women With Hormone Receptor Positive and HER2-negative Breast Cancer That Has Spread
Status: COMPLETED
Study type: INTERVENTIONAL
Conditions: Breast Neoplasms
Interventions: DRUG: Xentuzumab|DRUG: Placebo|DRUG: Everolimus|DRUG: Exemestane
Sponsor: Boehringer Ingelheim